StocksMedium•9 November 2026•
1 min read
Janux Therapeutics Announces Positive Phase 1 Results for JANX011
Key Facts
1Janux Therapeutics announced positive initial Phase 1 clinical results for JANX011 in healthy volunteers.
2The drug supports planned clinical development strategies for treating autoimmune diseases.
Janux Therapeutics announced positive initial Phase 1 clinical results for its drug candidate JANX011 in healthy volunteers. The company stated via Business Wire that the data supports planned clinical development strategies for treating autoimmune diseases, marking the first program from its proprietary ARM platform.
The results validate the safety and mechanism of the ARM platform in humans, enabling the company to proceed with development for autoimmune patients. In equity markets, JANX closed at $17.63 on November 6, 2026, having reached a session high of $17.81.